A Non-interventional Study to Assess the Safety and Efficacy of First Line Therapy With Vectibix® in Combination With FOLFIRI and to Validate a Prognostic Score in Adult Patients With RAS Wild-type Metastatic Colorectal Cancer in a Real World Setting (VALIDATE)
Latest Information Update: 29 Apr 2024
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms VALIDATE
- Sponsors iOMEDICO AG
- 23 Apr 2024 Status changed from active, no longer recruiting to completed.
- 24 Oct 2023 Updated second interim analysis Results presented at the 48th European Society for Medical Oncology Congress
- 16 Oct 2023 According to an Amgen media release, updated interim results from this study will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid.